Achieve Life Sciences, Inc. (ACHV), a late-stage specialty pharmaceutical company, said Monday it has confirmed the promotion of Mark Rubinstein from Interim Chief Medical Officer to Chief Medical Officer (CMO).
Since Dr. Rubinstein began his tenure as Interim CMO in September 2025, the company has achieved significant clinical and regulatory milestones, and he co-authored the recent paper in Thorax of data demonstrating cytisinicline's potential efficacy and tolerability for smoking cessation in individuals with COPD.
"Dr. Rubinstein has been an excellent addition to our leadership team during this pivotal period," said Rick Stewart, President and Chief Executive Officer of Achieve Life Sciences. "His reputation and expertise in nicotine cessation strengthens our medical leadership as we advance toward regulatory review. We are pleased to confirm his appointment to the permanent CMO role, and we're confident the team will continue to drive our progress forward."
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.